Cases & Deals

  • Home
  • Practices
  • Idenix enforces patent against Gilead in Germany over sofosbuvir

Share

Idenix enforces patent against Gilead in Germany over sofosbuvir

April 2022

Client(s) Idenix Pharmaceuticals LLC

Jones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C. Subject matter is nucleoside analogs and prodrugs for treating Flaviviridae infections, including HCV.

Idenix v. Gilead Sciences et al, Landgericht Düsseldorf, Az: 4c O 5/14

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.